Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

Background: Current guidelines recommend the use of inhaled corticosteroids (ICSs ... the magnitude of the benefits of LABA/ICS therapy did not reach that of the criteria for predefined clinically ...

there are combination inhalers that combine LABAs with LAMAs, LABAs with ICS, and LABAs with LAMAs and ICS. Using these drugs in combination can often improve long-term control. Within each class ...

Both ICS and LABA/ICS products are administered by inhalation ... FEV1: Forced expiratory volume in 1 s; ICS: Inhaled corticosteroid; LMA: Leukotriene motifying agent.Reproduced with permission ...

Formoterol (found in Symbicort, Dulera, and as a generic) is an example of a quick-acting LABA. Unfortunately ... that also ...

it was 3:1 [randomization], assigning the three groups to step-wide reduction in ICS doses tolerated using ICS inhaled ...

TUESDAY, Oct. 29, 2024 (HealthDay News) — For patients with asthma, inhaled corticosteroids (ICS) combined with short-acting β agonists (SABA) and ICS combined with the long-acting β agonist ...